That is probably low on their list, I doubt they will get to it for a couple of years (assuming they are not bought out once either mono or cancer results come in). I really hope it is not Gilead, what would be worse than their previous overpaying mistake? Overlooking a new therapy that they could have bought cheap at one time but didn’t, and it takes away 30% of your market.